Shaff Eric D. 4
4 · Seres Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Seres (MCRB) Director Eric Shaff Sells 259 Shares After RSU Vest
What Happened
Eric D. Shaff, a director of Seres Therapeutics (MCRB), reported settlement of restricted stock units (RSUs) and a small open‑market sale on February 15, 2026. The Form 4 shows 723 shares acquired via exercise/conversion (RSU settlement). Separately, Shaff sold 259 shares in an open‑market transaction at $8.47 per share for proceeds of $2,194. The filing also reports two other exercise/conversion entries (391 and 333 shares) reported as disposed with $0 proceeds (see Key Details/footnotes).
Key Details
- Transaction date: February 15, 2026; Form 4 filed February 18, 2026 (no late‑filing flag indicated).
- Open‑market sale: 259 shares at $8.47, proceeds $2,194. Sale was effected under a Rule 10b5‑1 plan “solely with the intent to cover taxes” (Footnote F2).
- RSU settlement/exercise: 723 shares acquired via exercise/conversion (reported as “M”); additional 391 and 333 shares reported as exercise/conversion with $0 proceeds (these entries reflect share disposition/withholding in connection with RSU settlement as described in footnotes).
- Shares owned after the transactions: not specified in the provided filing data.
- Footnotes: F1 clarifies each RSU = right to one common share; F2 confirms the sale was under a 10b5‑1 plan to cover taxes; F3–F4 outline the RSU vesting schedule (25% vested Feb 15, 2024 and Feb 15, 2025, remainder vest quarterly thereafter; RSUs have no expiration).
Context
This activity reflects RSU settlement and routine tax‑related share disposition rather than an opportunistic open‑market investment: one small block (259 shares) was sold under a pre‑existing 10b5‑1 plan to cover taxes arising from vesting. The $2.2k sale amount is modest and does not by itself signal a material change in insider sentiment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-15+723→ 11,836 total - Sale
Common Stock
[F2]2026-02-15$8.47/sh−259$2,194→ 11,577 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-15−391→ 1,564 total→ Common Stock (391 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-02-15−333→ 2,656 total→ Common Stock (333 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.